Overview

Riluzole in Women With Stage I, Stage II, or Stage IIIA Breast Cancer

Status:
Withdrawn
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer. Riluzole may help slow the growth of tumor cells. PURPOSE: This phase I trial is studying riluzole in women with stage I, stage II, or stage IIIA breast cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Barbara Ann Karmanos Cancer Institute
Collaborator:
National Cancer Institute (NCI)
Treatments:
Riluzole